Document is current

Article History

Received: 8 October 2024

Accepted: 28 January 2025

First Online: 28 February 2025

Declarations

:

: The study was approved by the ethic committee of Hospital Clínico Universitario de Valencia (2018/063, 2021/083), and all patients signed an informed consent.

: Not applicable.

: FP declares institutional research funding from Merck Serono, travel support from Diatech Pharmacogenetics, editorial role for Journal of Experimental and Clinical Cancer Research and Frontiers in Oncology, non-remunerated role as Coordinator of Young Translational Research Group of Gruppo Oncologico Italia Meridionale (GOIM). AC declares speaker’s engagement from Amgen, Foundation Medicine, Merck Serono and Roche; advisory role from Amgen, AnHeart Therapeutics, Merck Serono, Roche and Transgene; funding as local PI from Actuate Therapeutic, Adaptimmune, Amcure, Amgen, Astellas, AstraZeneca, Bayer, BeiGene, BMS, FibroGen, Genentech, Lilly, MedImmune, Merck Serono, MSD, Natera, Novartis, Servier, Sierra Oncology, Takeda and Replimmune; editorial role from Annals of Oncology, ESMO Open and Cancer Treatment Reviews; non-remunerated role as General and Scientific Director of INCLIVA Biomedical Research Institute. TF declares speaker’s engagement from Amgen, Bayer, Bristol, Lilly, MSD, Roche and Servier; non-remunerated PI role from Adapt Immune, Beigene and Daiichi Sankyo and advisory role for Amgen, MSD and Astrazeneca. NT declares advisory board or speaker fees from Merck Serono, Servier, Pfizer, Natera, and Guardant Health. VG discloses research funding Bayer, Boehringer, Roche and institutional funding Amcure, Astelas, Astra Zeneca, Bayer, BeiGene, BMS, FibroGen, Genentech, Lilly, Medimmune, Merck Serono, MSD, Natera, Novartis, Roche, Servier, Sierra Oncology, Takeda. SR declares research fundings from Roche, Pfizer, Novartis, Janssen, GSK, Inspirna, Scandion Oncology, Nouscom Company; advisory role from Pierre Fabre; travel support from Servier. DR declares institutional research funding from Tesaro, AbbVie, Novartis, Merus, Roche, Relay Therapeutics, HiFiBiO inc. All remaining authors have declared no conflicts of interest.